Next Article in Journal
Human Lectins and Their Roles in Viral Infections
Next Article in Special Issue
Scopoletin Protects against Methylglyoxal-Induced Hyperglycemia and Insulin Resistance Mediated by Suppression of Advanced Glycation Endproducts (AGEs) Generation and Anti-Glycation
Previous Article in Journal
Characterisation of Mediterranean Grape Pomace Seed and Skin Extracts: Polyphenolic Content and Antioxidant Activity
Previous Article in Special Issue
Activity of Alkaloids on Peptic Ulcer: What’s New?
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(2), 2208-2228; doi:10.3390/molecules20022208

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, Vienna 1090, Austria
*
Authors to whom correspondence should be addressed.
Academic Editor: Patricia Valentao
Received: 24 October 2014 / Revised: 11 November 2014 / Accepted: 26 November 2014 / Published: 29 January 2015
(This article belongs to the Special Issue Alkaloids: Novel Therapeutic Perspectives)
View Full-Text   |   Download PDF [2025 KB, uploaded 29 January 2015]   |  

Abstract

The plant indole alkaloid ibogaine has shown promising anti-addictive properties in animal studies. Ibogaine is also anti-addictive in humans as the drug alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug and despite safety concerns, ibogaine is currently used as an anti-addiction medication in alternative medicine in dozens of clinics worldwide. In recent years, alarming reports of life-threatening complications and sudden death cases, temporally associated with the administration of ibogaine, have been accumulating. These adverse reactions were hypothesised to be associated with ibogaine’s propensity to induce cardiac arrhythmias. The aim of this review is to recapitulate the current knowledge about ibogaine’s effects on the heart and the cardiovascular system, and to assess the cardiac risks associated with the use of this drug in anti- addiction therapy. The actions of 18-methoxycoronaridine (18-MC), a less toxic ibogaine congener with anti-addictive properties, are also considered. View Full-Text
Keywords: anti-addiction therapy; cardiotoxicity; drug-induced long QT; hERG channel inhibition; ibogaine; indole alkaloid; 18-methoxycoronaridine; noribogaine; Torsade de Pointes arrhythmias anti-addiction therapy; cardiotoxicity; drug-induced long QT; hERG channel inhibition; ibogaine; indole alkaloid; 18-methoxycoronaridine; noribogaine; Torsade de Pointes arrhythmias
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Koenig, X.; Hilber, K. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules 2015, 20, 2208-2228.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top